Levetiracetam Tablet, Film Coated
Product Images NDC 60687-657

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 60687-657). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000 mg Levetiracetam Tablet Blister (1000 mg Blister)

Sheet of ten identical Levetiracetam 1000 mg film-coated tablet labels showing the proprietary name, strength, a barcode, lot number, expiration date area, and the labeler American Health Packaging, Columbus, Ohio.*

FDA Label Image

1000 mg Levetiracetam Tablets Carton (1000 mg Carton)

Levetiracetam Tablets USP 1000 mg film-coated tablets in a 100-count (10 x 10) package. The label includes dispensing instructions for pharmacists and storage guidelines. It is labeled for prescription use only and distributed by American Health Packaging, Columbus, Ohio.*

FDA Label Image

500 mg Levetiracetam Tablet Blister (500 mg Blister)

Levetiracetam 500 mg film-coated tablet labels from American Health Packaging. Each label displays the drug name, strength, dosage form, barcode, lot number placeholder, and expiration date placeholder. The labels indicate oral route and include manufacturer details from Columbus, Ohio.*

FDA Label Image

500 mg Levetiracetam Tablets Carton (500 mg Carton)

Levetiracetam 500 mg film-coated tablets label showing a package size of 100 tablets (10 x 10) for oral use. The label includes instructions for pharmacists to dispense a medication guide, storage temperature recommendations, and a notice to keep the drug out of reach of children. It is labeled for prescription use only and distributed by American Health Packaging, Columbus, Ohio.*

FDA Label Image

Ahp65701

Levetiracetam 1000 mg film-coated oval tablet with code E 11 imprinted on one side and plain on the other. The tablet is beige in color and measures approximately 18 mm in length. It is an oral dosage form labeled by American Health Packaging.*

FDA Label Image

Ahp66801

Levetiracetam 1000 mg film-coated tablet, oval and white, scored with imprint 'E 13' on one side and plain on the other. The image includes a millimeter scale for size reference. Labeler is American Health Packaging.*

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Figure 1)

A bar chart showing responder rates (≥50% reduction from baseline) in a clinical study comparing placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart presents the percentage of patients responding, with placebo at 7.4%, Levetiracetam 1000 mg/day at 37.1%, and Levetiracetam 3000 mg/day at 39.6%.*

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Figure 2)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' displaying the percentage of patients achieving this response. The chart compares placebo with Levetiracetam 1000 mg/day and 2000 mg/day. Responder rates are 6.3% for placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day, with statistical significance indicated for Levetiracetam doses versus placebo.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Figure 3)

A bar chart titled 'Responder Rate (>=50% Reduction from Baseline) in Study 3' comparing the percentage of patients responding to Placebo versus Levetiracetam 3000 mg/day. The chart shows 14.4% response for Placebo (N=104) and 39.4% response for Levetiracetam (N=180), with a note indicating statistical significance versus placebo.*

FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Figure 4)

A bar graph comparing the responder rate, defined as at least 50% reduction from baseline, between placebo and Levetiracetam treatment groups in Study 4. The graph shows approximately 19.6% response with placebo and 44.6% with Levetiracetam, indicating a statistically significant difference.*

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Figure 5)

A bar chart titled 'Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5.' It shows two bars comparing placebo (N=51) at approximately 19.6% and levetiracetam (N=58) at approximately 43.1%, indicating a higher response rate for levetiracetam. An asterisk denotes statistical significance versus placebo.*

FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Figure 6)

Bar chart showing responder rates (≥50% reduction from baseline) in partial generalized tonic-clonic (PGTC) seizure frequency per week in Study 7 comparing Placebo and Levetiracetam groups. The chart indicates 45.2% responder rate for Placebo (N=84) and 72.2% for Levetiracetam (N=79), with statistically significant difference marked for Levetiracetam.*

FDA Label Image

Structural Formula (Structure)

Chemical structure of levetiracetam, showing its molecular ring and functional groups, consistent with the active ingredient in the medication Levetiracetam.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.